1. Home
  2. Directory
  3. Connecticut
  4. New Haven
  5. Clinical Nurse Specialist
  6. NPI Profile
  7. Prescriptions 1396041539

GINEESHA A ABRAHAM APRN
Prescription History 1396041539
Clinical Nurse Specialist - Oncology in New Haven, CT


Quality Rating: 73.56 out of 100 score

NPI Status: Active since February 06, 2011

Contact Information

20 YORK ST
SMILOW CANCER HOSPITAL, BREAST CENTRE
NEW HAVEN, CT
ZIP 06510
Phone: (203) 200-2328

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GINEESHA A ABRAHAM APRN, an active Oncology specialist practicing in New Haven, CT. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 498 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 318 claims alone.

Medication Index

A
E
I
L
T
V
No matching medications currently found on file.

Alprazolam

Generic Formulation: AlprazolamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 546
CT State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills67.4
Peer Average Days Supply1,811
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.7% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $136.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.22

State Avg Cost Per Claim

$9.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)

Therapeutic Applications

Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 318
30-Day Fills 902.9
Days Supply 27,087
CT State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills167.4
Peer Average Days Supply4,990
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 374.6% higher than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,724.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.72

State Avg Cost Per Claim

$32.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 59.0
Days Supply 1,770
CT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills59.3
Peer Average Days Supply1,771
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,659.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$463.44

State Avg Cost Per Claim

$306.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Ibrance

Generic Formulation: PalbociclibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.2
Days Supply 855
CT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply733
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $490,588.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,352.95

State Avg Cost Per Claim

$14,911.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 54
30-Day Fills 126.8
Days Supply 3,804
CT State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills100.0
Peer Average Days Supply2,989
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 35.0% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,956.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.23

State Avg Cost Per Claim

$34.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 36
30-Day Fills 108.0
Days Supply 3,239
CT State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills77.5
Peer Average Days Supply2,311
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $944.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.24

State Avg Cost Per Claim

$42.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Verzenio

Generic Formulation: AbemaciclibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 420
CT State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.3
Peer Average Days Supply603
Conservative Utilization

This provider writes prescriptions for this formulation 31.8% less frequently than the standard regional baseline metric for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $246,107.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,407.19

State Avg Cost Per Claim

$13,816.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer. Abemaciclib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GINEESHA A ABRAHAM APRN provides transparency into local medical care patterns within New Haven, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.